Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system

International Journal of Molecular Medicine

Volumn 30, Issue 4, 2012, Pages 953-959

  Baek, Jong Suep ^a   So, Jae Woo ^a,c   Shin, Sang Chul ^b   Cho, Cheong Weon ^a  

^a Chungnam National University   (South Korea)

^b Chonnam National University   (South Korea)

^c Research and Development Center   (South Korea)

Author keywords

Cellular uptake; Hydroxypropyl cyclodextrin; Lymphatic delivery; Paclitaxel; Solid lipid nanoparticle; Surface modified

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; PACLITAXEL; SOLID LIPID NANOPARTICLE;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BETA-CYCLODEXTRINS; CACO-2 CELLS; CELL SURVIVAL; DRUG CARRIERS; HUMANS; MALE; NANOPARTICLES; NEOPLASMS; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84866484085     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1086     Document Type: Article

References (24)

1. Shenoy VS, Rajyaguru TH, Gude RP and Murthy RS: Studies on paclitaxel-loaded glyceryl monostearate nanoparticles. J Microencapsul 26: 471-478, 2009.
2. Schellens JH, Malingre MM, Kruijtzer CM, Bardelmeijer HA, Tellingen O and Schinkel AH: Modulation of oral bioavailability of anticancer drugs from mouse to man. Eur J Pharm Sci 2: 103-110, 2002.
3. Bode C, Trojan L, Weiss C, Kraenzlin B, Michaelis U, Teifel M, Alken P and Michel MS: Paclitaxel encapsulated in cationic liposomes: A new option for neovascular targeting for the treatment of prostate cancer. Oncol Rep 22: 321-326, 2009.
4. Bilensoy E, Gürkaynak O, Doǧan AL and Hincal AA: Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery. Int J Pharm 347: 163-170, 2008.
5. Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA and Khan ZI: Microemulsions: a novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul 3: 238-257, 2008.
6. Sawant RR and Torchilin VP: Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm 374: 114-118, 2009.
7. Guo K and Chu CC: Biodegradable and injectable paclitaxel-loaded poly(ester amide)s microspheres: fabrication and characterization. J Biomed Mater Res B Appl Biomater 89: 491-500, 2009.
8. Xu P, Gullotti E, Tong L, Highley CB, Errabelli DR, Hasan T, Cheng JX, Kohane DS and Yeo Y: Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles. Mol Pharm 6: 190-201, 2008.
9. Li X, Li P, Zhang Y, Zhou Y, Chen X, Huang Y and Liu Y: Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously. Pharm Res 27: 1498-1511, 2010.
10. Luo J, Xiao K, Li Y, Lee JS, Shi L, Tan YH, et al: Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjug Chem 21: 1216-1224, 2010.
11. Xiao K, Luo J, Fowler WL, Li Y, Lee JS, Xing L, et al: A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 30: 6006-6016, 2009.
12. Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM, et al: The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32: 3435-3446, 2011.
13. Mehnert W and Mäder K: Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47: 165-196, 2001.
14. Müller RH, Radtke M and Wissing SA: Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetics and dermatological preparations. Adv Drug Del Rev 54 (Suppl 1): S131-S155, 2002.
15. Yuan H, Chen J, Du YZ, Hu FQ, Zeng S and Zhao HL: Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Colloids Surf B Biointerfaces 58: 157-164, 2007.
16. Patel R and Purohit N: Physico-chemical characterization and in vitro dissolution assessment of clonazepam-cyclodextrins inclusion compounds. AAPS PharmSciTech 10: 1301-1312, 2009.
17. Hamada H, Ishihara K, Masuoka N, Mikuni K and Nakajima N: Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins. J Biosci Bioeng 102: 369-371, 2006.
18. Trickler WJ, Nagvekar AA and Dash AK: A novel nanoparticle formulation for sustained paclitaxel delivery. AAPS PharmSciTech 9: 486-493, 2008.
19. Fang YP, Lin UK, Su YH and Fang JY: Tryptanthrin-loaded nanoparticles for delivery into cultured human breast cancer cells, MCF7: the effects of solid lipid/liquid lipid ratios in the inner core. Chem Pharm Bull 59: 266-271, 2011.
20. Sanjula B, Shah FM, Javed A and Alka A: Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target 17: 249-256, 2009.
21. Irie T and Uekama K: Pharmaceutical applications of cyclodextrin. III. Toxicological issues and safety evaluation. J Pharm Sci 86: 147-162, 1997.
22. Aji Alex MR, Chacko AJ, Jose S and Souto EB: Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci 42: 11-18, 2011.
23. Cho CW, Kim DC and Shin SC: Effect of ultrasound-induced hyperthermia on cellular uptake of P-gp substrate and non-P-gp substrate in MDR cells. J Kor Pharmaceut Sci 31: 131-135, 2007.
24. Li Y, Xiao K, Luo J, Lee J, Pan S and Lam KS: A novel size-tunable nanocarrier system for targeted anticancer drug delivery. J Control Release 144: 314-323, 2010.